PVRL2 influenced annualized EDSS accrual (+0.06 points/year, 95%CI: 0.02–0.11, P = 0.010) in the whole cohort and in MS-only analyses EDSS [+0.09 points/year, 95% CI: (0.02, 0.015), P = 0.012]. This evidence concerns the gene NECTIN2 and myeloid sarcoma.